Omega-3 fatty acids and blood-based biomarkers in Alzheimer's disease and mild cognitive impairment: A randomized placebo-controlled trial
Lin PY, Cheng C, Satyanarayanan SK, Chiu LT, Chien YC, Chuu CP, Lan TH, Su KP
Brain, behavior, and immunity · 75 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Ministry of Education
- Universidad u hospital
- China Medical University Hospital
- Gobierno
- Ministry of Science and Technology, Taiwan
- Universidad u hospital
- Universidade de Macau
- Gobierno
- National Health Research Institutes
- Universidad u hospital
- China Medical University, Taiwan
- Universidad u hospital
- Tainan Municipal An-Nan Hospital
- Subvenciones
- China Medical University Hospital (DMR‐109‐102); China Medical University Hospital (DMR-HHC-109-11); Ministry of Science and Technology, Taiwan (MOST110-2320-B039-047-MY3); Ministry of Science and Technology, Taiwan (MOST109-2320-B039-066); China Medical University Hospital (CMU104-S-16-01); China Medical University Hospital (DMR‐109‐244); Ministry of Education (CMU110-AWARD-02); China Medical University Hospital (CRS-108-048); Ministry of Science and Technology, Taiwan (MOST110-2320-B039-048-MY2); Universidade de Macau (110-26); Universidade de Macau (ANHRF109-31); China Medical University Hospital (CMU103‐BC‐4‐1); Ministry of Education (DMR-HCC-109-12); Ministry of Science and Technology, Taiwan (MOST110-2321-B006-004); National Health Research Institutes (MYRG2018-00242-ICMS); Ministry of Science and Technology, Taiwan (110-2811-B-039-507); Ministry of Education (DMR-110-124); Ministry of Education (DMR-HHC-110-10); Ministry of Education (DMR-108-216); Universidade de Macau (110-13); China Medical University, Taiwan (CMRC-CMA-3); Ministry of Education (CMU108-SR-106)
Según 7 financiadores declarados.
Publicación
- Publicado
- 2021-10-29 · Brain Behav Immun · vol. 99 · págs. 289–298
- Editorial
- Elsevier BV
- Citado
- 93 citas · más que el 98% de estudios similares · 6.6× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 82 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Dementia and Cognitive Impairment Research · Alzheimer's disease research and treatments
- Palabras clave
- omega-3 fatty acids, docosahexaenoic acid, eicosapentaenoic acid, Alzheimer's disease, mild cognitive impairment, n-3 PUFA supplementation, inflammatory cytokines, carbon tetrachloride, blood biomarkers, cognitive decline, functional capacity, constructional praxis, anti-inflammatory activity, veterans, depression in dementia
- MeSH
- humans, alzheimer disease, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, double-blind method, dietary supplements, biomarkers, cognitive dysfunction
8 autores
- Pan-Yen Lin🇹🇼China Medical University; China Medical University Hospital
- Chin Cheng🇹🇼China Medical University; China Medical University Hospital
- Senthil Kumaran Satyanarayanan🇹🇼🇲🇴China Medical University; University of Macau; China Medical University Hospital
- Lu‐Ting Chiu🇹🇼China Medical University; China Medical University Hospital
- Yu-Chuan Chien🇹🇼China Medical University; China Medical University Hospital
- Chih‐Pin Chuu🇹🇼National Health Research Institutes; China Medical University
- Tsuo‐Hung Lan🇹🇼 · autor de correspondenciaNational Yang Ming Chiao Tung University; National Health Research Institutes; Ministry of Health and Welfare
- Kuan‐Pin Su🇹🇼 · autor de correspondenciaChina Medical University; An-Nan Hospital; China Medical University Hospital
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Increased serum levels of pro-inflammatory biomarkers are consistently associated with cognitive decline. The omega-3 unsaturated fatty acids (n-3 PUFAs) had been linked to slowing cognitive decline due to their potential anti-inflammatory effects. To our knowledge, the different regiments of pure DHA, pure EPA, and their combination on various associated symptoms of dementia, including a mild form of cognitive impairment (MCI) and Alzheimer's disease (AD), have never been studied.
Methods
This multisite, randomized, double-blind, placebo-controlled trial was conducted at two veteran's retirement centers and one medical center in central Taiwan between 2013 and 2015. 163 MCI or AD patients were randomly assigned to placebo (n = 40), docosahexaenoic acid (DHA, 0.7 g/day, n = 41), eicosapentaenoic acid (EPA, 1.6 g/day, n = 40), or EPA (0.8 g/day) + DHA (0.35 g/day) (n = 42) group for 24 months. The results were measured as the cognitive and functional abilities, biochemical, and inflammatory cytokines profiles. Chi-square tests, two-sample t-test, ANOVA, and linear mixedeffects models were conducted with p < 0.05.
Results
131 (80%) participants had completed the trial with all cognitive, functional, and mood status assessments. The statistically significant difference between the placebo and treatment groups was not determined, concerning the changes in cognitive, functional, and mood status scores, the biochemical profiles, and inflammatory cytokines levels. However, EPA was found to reduce the C-C motif ligands 4 (CCL4) level (p < 0.001). Additionally, EPA could reduce the constructional praxis (p < 0.05) and spoken language ability scores (p < 0.01), and DHA also reduced the spoken language ability score (p < 0.05).
Conclusion
Overall, n-3 PUFAs supplements did not reduce cognitive, functional, and depressive symptom outcomes, but spoken language ability and constructional praxis subitems of ADAS-cog. These findings show that attention to clinical heterogeneity in dementia is crucial when studying nutrients interventions, such as n-3 PUFAs. In addition, with small effect size CCL4 is a better indicator than other inflammatory cytokines for EPA treatment response.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.